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Background: Fibromyalgia is associated with substantial socioeconomic loss and, despite considerable research
including numerous randomized controlled trials (RCTs) and systematic reviews, there exists uncertainty regarding
what treatments are effective. No review has evaluated all interventional studies for fibromyalgia, which limits
attempts to make inferences regarding the relative effectiveness of treatments.
Methods/design: We will conduct a network meta-analysis of all RCTs evaluating therapies for fibromyalgia to
determine which therapies show evidence of effectiveness, and the relative effectiveness of these treatments. We
will acquire eligible studies through a systematic search of CINAHL, EMBASE, MEDLINE, AMED, HealthSTAR,
PsychINFO, PapersFirst, ProceedingsFirst, and the Cochrane Central Registry of Controlled Trials. Eligible studies will
randomly allocate patients presenting with fibromyalgia or a related condition to an intervention or a control.
Teams of reviewers will, independently and in duplicate, screen titles and abstracts and complete full text reviews
to determine eligibility, and subsequently perform data abstraction and assess risk of bias of eligible trials. We will
conduct meta-analyses to establish the effect of all reported therapies on patient-important outcomes when
possible. To assess relative effects of treatments, we will construct a random effects model within the Bayesian
framework using Markov chain Monte Carlo methods.
Discussion: Our review will be the first to evaluate all treatments for fibromyalgia, provide relative effectiveness of
treatments, and prioritize patient-important outcomes with a focus on functional gains. Our review will facilitate
evidence-based management of patients with fibromyalgia, identify key areas for future research, and provide a
framework for conducting large systematic reviews involving indirect comparisons.
Keywords: Fibromyalgia, Systematic review, Network meta-analysis, Multiple treatment comparison, Randomized
controlled trialsBackground
Fibromyalgia is a syndrome characterized by chronic
widespread pain and excessive tenderness at 11 of 18 spe-
cific muscle-tendon sites, for which no clear cause can be
found [1]. Approximately 2% of the general population in
the United States suffers from fibromyalgia, with women* Correspondence: bussejw@mcmaster.ca
1Department of Anesthesia, McMaster University, 1200 Main Street West,
Hamilton, Ontario L8S 4K1, Canada
2Department of Clinical Epidemiology and Biostatistics, McMaster University,
1200 Main Street West, Hamilton, Ontario L8S 4K1, Canada
Full list of author information is available at the end of the article
© 2013 Busse et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the oraffected ten times more often than men [2]. Similar preva-
lence rates have been reported in Canada (3.3%), Brazil
(4.4%) and Western European countries, including
Germany (3.2%), Spain (2.4%), Italy (2.2%), Sweden (2.5%),
France (1.4%), Italy (3.7%) and Portugal (3.6%) [3-8].
Treatment directed towards fibromyalgia is highly variable
and long-term prospective observational studies have
found that patient outcomes, even in specialized rheuma-
tology clinics, are typically poor [9,10].
Poor treatment outcomes have led to frustration
among patients and their clinicians, and contributed totd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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vational studies have found that 20% to 50% of persons
with fibromyalgia report that they are unable to work or
that they can work only a few days per month, and 27%
to 55% receive disability or social security payments. Of
those that do work, 36% experience an average of two or
more absences from work per month [11-13].
Physicians typically find fibromyalgia difficult to man-
age and patients with fibromyalgia are likely to be dissat-
isfied with treatment [14]. A recent survey of 1,200
primary care physicians in the United States (33% re-
sponse rate) found that only 14% of respondents indi-
cated very good or excellent satisfaction with managing
patients with fibromyalgia and other medically unex-
plained symptoms [15], and a study of 400 British gen-
eral practitioners (75% response rate) found that only
44% of respondents felt there were effective treatment
options available for this population [16].
There have been no less than 38 systematic reviews
addressing therapies for fibromyalgia [17-54]; however,
the large majority of reviews to date have explored ther-
apies in isolation or looked at a subgroup of treatments.
There have been two network meta-analyses we are
aware of that explored multiple therapies for fibromyal-
gia [51,52]. The first [52] restricted comparisons to
pharmacological treatments only and used the Jadad
scale to assess study quality [55], which has been criti-
cized as overly simplistic and placing too much em-
phasis on blinding [56]. The second [51] excluded
complementary and alternative medicine approaches,
had no assessment of study quality, and summarized
continuous data using the standardized mean difference,
which is vulnerable to differential variability in popula-
tions enrolled and adds challenges in interpreting the
magnitude and importance of treatment effects [57,58].
No review has looked at all interventional studies for
fibromyalgia, which limits attempts to make inferences
regarding the relative effectiveness of available treat-
ments. Further, none used the GRADE framework to
establish confidence in pooled estimates of treatment ef-
fect [59].
We will explore all therapies for fibromyalgia that have
been tested in randomized controlled trials (RCTs) and
use Bayesian mixed treatment comparison methods
(adjusted indirect comparisons) to complement the dir-
ect comparisons of the relative effects of competing
interventions in RCTs [60,61].
Methods/design
Protocol and registration
Our protocol is registered on PROSPERO (CRD4201200
3291), http://www.crd.york.ac.uk/PROSPERO.
Our paper conforms to the PRISMA guidelines for
reporting systematic reviews [62].Eligibility criteria
Trials eligible for our review will (1) have enrolled adult
patients (≥18 years of age) presenting with fibromyalgia
or a related condition (for example, myofascial pain
syndrome, fibrositis, fibromyositis, muscular rheuma-
tism, chronic generalized pain syndrome), and (2) have
randomized patients to an intervention or a control arm.
Information sources and search
We will identify relevant RCTs, in any language, by a sys-
tematic search of CINAHL, EMBASE, MEDLINE, AMED,
HealthSTAR, PsycINFO, PapersFirst, ProceedingsFirst,
and the Cochrane Central Registry of Controlled Trials,
from inception of the database, with relevant MeSH
headings. An experienced librarian (QM) developed a
sensitive search strategy for each individual database
(see Additional file 1). We will scan the bibliographies
of all retrieved trials and other relevant publications,
including reviews and meta-analyses, for additional
relevant articles.
Study selection
Twenty reviewers with experience in health research
methodology will work in pairs to screen, independently
and in duplicate, titles and available abstracts of identi-
fied citations and acquire the full text publication of any
article that either reviewer judge as potentially eligible.
The same reviewer teams will independently apply eligi-
bility criteria to the full text of potentially eligible trials.
Reviewers will resolve disagreements by consensus or, if
a discrepancy remains, through discussion with one of
two arbitrators (JWB or GHG).
Data collection process and data items
Using standardized forms (see Additional file 2) and a
detailed instruction manual that will be used to inform
specific tailoring of an online data abstraction program
(DistillerSR), ten teams of reviewers will extract data in-
dependently and in duplicate from each eligible study.
To ensure consistency across reviewers, we will con-
duct calibration exercises before starting the review.
Data abstracted will include demographic information,
methodology, intervention details, and all reported
patient-important outcomes. Reviewers will resolve dis-
agreements by discussion, and one of two arbitrators
(JWB or GHG) will adjudicate unresolved disagree-
ments. We will contact study authors to resolve any
uncertainties.
Two reviewers (GC, EAC) will independently extract
details on interventions and outcomes from all RCTs in
order to classify them into common intervention categor-
ies. The abstractors will develop the categories independ-
ently and then achieve consensus through discussion.
Outcomes will be classified into domains, based on the
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urement, and Pain Assessment in Clinical Trials
(IMMPACT) [63-70]. These consist of nine domains: pain;
physical and emotional functioning (including Quality of
Life); participant rating of improvement and satisfaction
with treatment; adverse events; participant disposition (for
example, adherence to the treatment regime and reasons
for premature withdrawal from the trial); role functioning
(that is, work and educational activities, social and recre-
ational activities, home and family care); interpersonal
functioning (that is, interpersonal relationships, sexual
activities); sleep; and fatigue.
Risk of bias in individual studies
Reviewers will assess risk of bias within each study with a
modified Cochrane risk of bias instrument which assesses
the following key domains: sequence generation; alloca-
tion concealment; blinding of participants, healthcare
professionals, outcome assessors, data collectors, and
data analysts; incomplete outcome data; selective out-
come reporting; and other sources of bias. Reviewers
will input response options of ‘definitely yes’, ‘probably
yes’, ‘probably no’, and ‘definitely no’ for each of the do-
mains, with ‘definitely yes’ and ‘probably yes’ ultimately
assigned low risk of bias and ‘definitely no’ and ‘prob-
ably no’ assigned high risk of bias [71]. Reviewers will
resolve disagreements by discussion, and one of two
arbitrators (JWB or GHG) will adjudicate unresolved
disagreements.
Direct comparisons meta-analyses
To pool outcome data for trials that compare the same
intervention with the same comparator, we will use
random effects meta-analyses, which are conservative in
that they consider both within and among study differ-
ences in calculating the error term used in the analysis
[11]. We will pool cross-over trials with parallel design
RCTs, using methods outlined in the Cochrane hand-
book to derive effect estimates [72]. Specifically, we will
perform a paired t-test for each cross-over trial if either
of the following are available: 1) the individual partici-
pant data; 2) the mean and SD (or standard error) of the
participant-specific differences between the intervention
and control measurements; 3) the mean difference and
one of the following: (i) a t-statistic from a paired t-test,
(ii) a p-value from a paired t-test, or (iii) a confidence
interval from a paired analysis; or 4) a graph of measure-
ments of the intervention arm and control arm from
which we can extract individual data values (pending
that the matched measurements for each individual can
be identified) [72]. If these data are not available, we will
approximate paired analyses by first calculating the
mean difference for the paired analysis (MD =ME - MC)
and the standard error of the mean difference:SE MDð Þ ¼ SDdiffffiffiffi
N
p , where N represents the number of par-
ticipants in the trial, and SDdiff represents the standard de-
viation of within-participant differences between the
intervention and control measurements [72]. If the stand-
ard error or standard deviation of within-participant differ-
ences is not available, we will impute the standard deviation
using methods outlined in the Cochrane Handbook [73].Ensuring interpretable results from pooled estimates of
effect
We will use a number of approaches to facilitate inter-
pretable results from our meta-analyses. For trials that
report dichotomous outcomes, we will calculate the odds
ratio (OR) to inform relative effectiveness. We will
acquire estimates of baseline risk from observational
studies or, if not available, from the median of the con-
trol group from eligible RCTs.
When pooling across trials that report continuous out-
comes using the same instrument, we will calculate the
weighted mean difference (WMD), which maintains the
original unit of measurement and represents the average
difference between groups [74]. Once the WMD has
been calculated, we will contextualize this value by
noting the corresponding minimally important differ-
ence (MID) - the smallest change in instrument score
that patients perceive is important. We will prioritize
use of anchor-based MIDs when available, and calculate
distribution-based MIDs when they are not.
Contextualizing the WMD through the MID can be
misleading because clinicians may interpret a WMD less
than the MID as suggesting that no patient obtains an
important benefit, which is not accurate. Therefore, we
will generate an estimate of the proportion of patients
who have benefited by applying the MID to individual
studies, estimating the proportions who benefit in each
study, and then aggregate the results in order to provide
a summary estimate of the proportion of patients who
benefit from treatment across all studies. Details of the
methods by which we will conduct this analysis are
presented immediately below in our discussion of situa-
tions in which investigators have used different instru-
ments to measure the same construct.
For trials that use different continuous outcome mea-
sures that address the same underlying construct, one
cannot calculate a weighted mean difference, and we will
therefore calculate a measure of effect called the
standardized mean difference (SMD) or ‘effect size’. This
involves dividing the difference between the intervention
and control means in each trial (that is, the mean differ-
ence) by the estimated between-person standard devi-
ation (SD) for that trial. The SMD expresses the
intervention effect in SD units rather than the original
units of measurement, with the value of a SMD
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between means) and the SD of the outcomes (the inher-
ent variability among participants).
This common approach to pooling continuous out-
come data is often problematic. If the heterogeneity of
patients is different across studies, the SD will vary
across studies. Therefore, given the same true difference
in outcome between intervention and control groups,
trials with more heterogeneous patients will show appar-
ently - but spuriously - smaller effects than trials enrolling
less heterogeneous patients. Furthermore, interpretation
of the magnitude of effect when represented as SD units is
not intuitive.
In order to address these issues, we will contextualize
the SMD value through MID units, which are not vul-
nerable to the distortions that varying heterogeneity of
populations can create and are more interpretable to
both clinicians and patients [58,75]. For outcome mea-
sures that have an established anchor-based MID we will
use this measure to convert the summary effect into OR.
We will complement this presentation by either
converting the summary effect into natural units of a
widely accepted instrument used to measure changes in
the domain of interest or, if such an instrument is not
available, we will substitute the MID for the SD (denom-
inator) in the SMD equation, which will result in more
readily interpretable MID units instead of SD units [58].
Finally, we will, as for SMD, provide a summary estimate
of the proportion of patients who benefit from treatment
across all studies
We illustrate this approach with the following
example. We will first describe how we will summarize
the outcome in MID units. Assume that a trial reports a
mean difference (MD) on a continuous outcome meas-
ure “X”, and assume that an anchor-based MID for
instrument X, MIDX, has been established. The esti-
mated MD is a random variable. If we standardize this
random variable by dividing it by the MIDX, we get a
new random variable, MD/MIDX. We know from basic
probability theory that because MIDX is a constant, the
variance of MD/MIDX is given by:
Var
MD
MID2X
 
¼ Var MDð Þ
MID2X
That is, the variance of the mean difference divided by
the square of the MID. Further, the standard error of
MD/MIDX is given by:
SE
MD
MID2X
 
¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
Var MDð Þ
MID2X
s
¼ SE SDð Þ
MIDX
Consider a meta-analysis that included k trials. The
first j trials use disease-specific instrument A, and thelast k-j trials use disease-specific instrument B. Let MDi
denote the mean difference observed in trial i, let MIDA
denote the MID established for instrument A, and let
MIDB denote the MID established for instrument B. Fur-
ther, let mi denote the MID standardized effect for trial i.
To pool results across trials using MIDs we must first
estimate the mi and its associated variance for all trials.
For i = 1, . . ., j we have:
mi ¼ MDiMIDA and Var mið Þ ¼
Var MDið Þ
MID2A
and for i = j + 1, . . ., k we have:
mi ¼ MDiMIDB and Var mið Þ ¼
Var MDið Þ
MID2B
By defining the trial weights as wi = Var(mi)
-1, we can
use the fixed-effect model inverse variance method to
pool the MID-standardized mean differences using the
formula:
m̂ ¼
Xk
i¼1
wi:mi
 !
=
Xk
i¼1
wi
 !
Where m̂ denotes the pooled MID-standardized mean
difference. The standard error of m̂ can be calculated
using the formula:
se m̂ð Þ ¼ 1=
Xk
i¼1
wi
 !
The associated confidence intervals can subsequently
be derived. MID-standardized mean differences can also
be combined in a random-effects model using weights
wi = (Var(mi) + τ
2)-1, where τ2 denotes the between-trial
variance.
This presentation does not address the risk that clini-
cians may interpret all mean effects below the MID as
unimportant, and presume important benefit for all pa-
tients when mean effects exceeds the MID. We will ad-
dress this issue by assuming normal distributions of data
and then calculating the proportions of participants in
the intervention and control groups in each study that
demonstrated an improvement greater than the MID
[76]. The results are then pooled across studies. If we
only have post-test data (rather than magnitude of
change), we will apply this approach if evidence exists
regarding meaningful thresholds. For instance, if one
knows that people with scores of less than 8 on the
Hamilton rating scale for depression (HAM-D) are con-
sidered to be not depressed, one could examine the pro-
portion of individuals below that threshold.
If such meaningful thresholds do not exist, we will use
post-test data and assume that the minimally important
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the minimally important difference between individuals.
Making this assumption, one can calculate the difference
in the proportion who benefit in intervention and control.
To do this, we will take the mean value in the control
group plus one MID unit, and calculate the proportion of
patients in each group above that threshold.
If an anchor-based MID has not been established for
all instruments, we will assume a meta-analysis control
group probability (pC) and use the SMD to calculate the
OR. Specifically, we will construct a conceptual meta-
analysis control group with mean μC, standard deviation
σC, and group size nC, and a conceptual meta-analysis
intervention group with mean μE, standard deviation σE,
and group size nE such that the SMD can be represented
as SMD = μE - μC and σE = σC = 1. We will set μC = 0 and
σC = 1, and our threshold (T) will be equal to Φ
-1(pC),
where Φ-1 is the inverse standard normal cumulative
distribution function. We will then use the derived
threshold to calculate the conceptual intervention group
probability (pE). The intervention group mean response
is assumed to follow a normal distribution with mean
SMD and a SD of 1. Thus, the intervention group prob-
ability is pE = 1 −Φ(T − SMD). Having estimated the
conceptual meta-analysis control and intervention group
probabilities from the pooled SMD, we will calculate the
OR as follows:
OR ¼ pE 1 pCð Þ
pC 1 pEð Þ
To calculate the 95% CI, we will use the above formu-
las substituting the upper and lower bounds of the SMD
confidence interval. We will complement this presenta-
tion by converting the SMD into natural units of a
widely accepted instrument used to measure changes in
the domain of interest or, if such an instrument is not
available, we will calculate the ratio of means [58].
Assessment of heterogeneity and subgroup analyses
We will examine heterogeneity of meta-analyses using
both a chi-squared test and the I2 statistic, the percent-
age of among-study variability that is due to true differ-
ences between studies (heterogeneity) rather than
sampling error (chance) [77,78]. We have generated the
following a priori hypotheses to explain variability be-
tween studies: (1) interventions will show larger effects
among trials enrolling ≥50% patients clearly defined as
meeting the American College of Rheumatology (ACR)
criteria for fibromyalgia [1] versus trials in which less
than 50% of subjects meet the ACR criteria; (2) larger ef-
fects in trials of patients in which receipt of disability
benefits or involvement in litigation was an exclusion
criteria versus those that did not exclude patients on thisbasis; and (3) studies with greater risk of bias will have lar-
ger effects than studies with lower risk of bias. We will
perform subgroup analyses on a component-by-compo-
nent basis if we detect variability within the individual risk
of bias components. We will conduct z-tests [79] to estab-
lish if subgroups differ significantly from each other [80].
Multiple comparison meta-analysis
We will examine the assumptions of similarity (for an
indirect treatment comparison) and consistency (for
mixed-treatment comparison) before conducting a net-
work meta-analysis. To assess relative effects of compet-
ing treatments, we will construct a random effects
model within the Bayesian framework using Markov
chain Monte Carlo methods in WinBUGS (MRC Bio-
statistics Unit, Cambridge, UK) [81]. We will model out-
comes in every treatment group of every study and
specify the relations among the effect sizes across studies
[82]. This method combines direct and indirect evidence
for any given pair of treatments. We will use the
resulting 95% credible intervals (CrIs) to assess treat-
ment effects [83]. We will assess the probability that
each treatment was the most efficacious regimen, the
second best, the third best, etcetera, by calculating the
effect size for each treatment compared with an arbitrary
common control group and counting the proportion of
iterations of the Markov chain in which each treatment
has the highest effect size, the second highest, etcetera.
A key assumption behind multiple treatments meta-
analysis is that the analyzed network is consistent; that
is, that direct and indirect evidence on the same com-
parisons do not disagree beyond chance. We will locate
and estimate inconsistencies by employing a mixed
treatment comparisons inconsistency model in the
Bayesian framework [84].
We will use a recent user’s guide published in the
Journal of American Medical Association (of which two
of our team were authors: KT and GHG) to assess the
strength of inferences and credibility of our network
meta-analysis [85]. We will use this guide to critically
appraise our work in 3 domains and 12 subdomains
(Table 1).
Confidence in pooled estimates of effect
Reviewers will, independently and in duplicate, assess
the confidence in effect estimates for all outcomes using
the GRADE (Grading of Recommendations, Assessment,
Development and Evaluation) rating system [86]. In the
GRADE system of rating quality of evidence for each
outcome, randomized trials begin as high quality evi-
dence, but may be rated down by one or more of five
categories of limitations: (1) risk of bias, (2) consistency,
(3) directness, (4) imprecision, and (5) reporting bias
[80]. After considering these categories, the confidence
Table 1 Critical appraisal guide for a Network Meta-Analysis [85]
Critical appraisal criteria Specific items
A. Are the results of the study valid?
Did the review explicitly address a sensible clinical question?
Was the search for relevant studies exhaustive?
Were there major biases in the primary studies?
B. What are the results?
What was the amount of evidence in the network?
Were the results similar from study to study?
Were the results consistent in direct and indirect comparisons?
What were the overall treatment effects and their uncertainty, and how did the treatments rank?
Were the results robust to sensitivity assumptions and potential biases?
C. How can I apply the results to patient care?
Were all patient-important outcomes considered?
Were all potential treatment options considered?
Are any postulated subgroup effects credible?
What is the overall quality and what are limitations of the evidence?
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follows: ‘high’ quality of evidence (we are very confident
that the true effect lies close to that of the estimate of
the effect); ‘moderate’ quality of evidence (we are moder-
ately confident in the effect estimate and the true effect
is likely to be close to the estimate of the effect, but
there is a possibility that it is substantially different);
‘low’ quality of evidence (our confidence in the effect
estimate is limited and the true effect may be substan-
tially different from the estimate of the effect); and ‘very
low’ quality of evidence (we have very little confidence
in the effect estimate and the true effect is likely to be
substantially different from the estimate of effect) [86].
We will assess publication bias by visually observing
asymmetry of the funnel plot for each outcome. As a
rule of thumb [87], tests for funnel plot asymmetry
should be used only when there are at least ten studies
included in the meta-analysis. Otherwise the power of
the tests is too low to distinguish chance from real
asymmetry. We will report our results by type of inter-
vention (for example, psychotherapy, analgesics, antide-
pressants) and focus on patient-important outcomes.
We will report all direct comparison data, and only
complement these data with indirect comparison data if
the strength of inferences from direct comparisons is
similar or less than the strength of inferences from indir-
ect comparisons. If there are no direct comparisons
available, we will report indirect comparison data only.
Knowledge translation
We plan to create a stakeholder advisory committee with
representation from ambulatory health care providers
from across Ontario, Canada as well as from key organiza-
tions. We will ensure that we have geographically diverserepresentation including primary care providers who prac-
tice in rural areas of the province. Members of our stake-
holder committee will be invited to attend our planning
meeting and share their input/advice with members of the
review team.
Our team also will engage in an end-of-study knowledge
translation workshop. The purpose of this activity will be
to share our findings with key relevant stakeholders
(researchers, clinicians and decision-makers) in order to
identify future opportunities for dissemination, beyond
traditional peer-reviewed publications, with our stake-
holders, discuss how to maximize uptake of our findings in
patient education and clinical practice, and determine fu-
ture research directions. The overall goal of the workshop
is to develop an agenda that will establish directions to
develop and implement our research findings into practice.
The following strategies will be used to promote
awareness of the stakeholder meeting findings according
to the Ottawa Model of Research Use in which informa-
tion is tailored to specific audiences: (1) distribution of
findings to all involved participants for further input,
sharing within their organization, and for sharing with
their own stakeholders via newsletter, web site, or other
methods; (2) presentation at relevant peer-reviewed and
community conferences; and (3) publication in an open-
source peer-reviewed journal. We anticipate that this
meeting will identify new areas of inquiry for research
and practice, such as the development of new educa-
tional tools for patients and clinicians. We also antici-
pate that new collaborations and networks will be
created that will support the identified work going for-
ward. Any groups identified through the meeting will be
included as part of the report back to the stakeholders
in order to broadly disseminate the findings.
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Our review will evaluate all treatments for fibromyalgia,
provide relative effectiveness of treatments, and evaluate
the quality of the evidence in a thorough and consistent
manner using the GRADE approach [88-90]. Addition-
ally, many existing reviews focus on surrogate outcomes,
such as number of tender points, stiffness, range of mo-
tion, or laboratory values; we will prioritize patient-
important outcomes such as function and quality of life.
The results of our systematic review will be of interest
to a broad audience including patients diagnosed with
fibromyalgia, health professionals managing fibromyal-
gia, employers, human resource professionals, insurers/
compensation boards, and labor groups. Our review will
facilitate evidence-based management of patients with
fibromyalgia, identify key areas for future research, and
provide a framework for conducting large systematic re-
views involving indirect comparisons.
Additional files
Additional file 1: Appendix A. Search Strategy.
Additional file 2: Appendix B. Data Abstraction Forms.
Abbreviations
CrIs: Credible intervals; GRADE: Grading of Recommendations, Assessment,
Development and Evaluation; MD: Mean difference; MID: Minimally
important difference; OR: Odds ration; RCTs: Randomized controlled trials;
SD: Standard deviation; SMD: Standardized mean difference; WMD: Weighted
mean difference.
Competing interests
JWB acts as a consultant to Prisma Health Canada, a private incorporated
company funded by employers and insurers that consults on and manages
long-term disability claims. All other authors report no conflicts of interest.
Authors’ contributions
JWB, KT and GHG conceived the study design. JWB and SE completed the
first draft of the manuscript. All authors reviewed several drafts of the
manuscript and approved the final version.
Acknowledgements
This systematic review is funded by a Canadian Institutes of Health Research
Knowledge Synthesis Grant. The development of this protocol was funded
in-part by a grant from the Ontario Chiropractic Association. JWB is
supported by a New Investigator Award from the Canadian Institutes of
Health Research and Canadian Chiropractic Research Foundation. SE is
supported by a Canadian Institutes of Health Research Doctoral Award. JJR is
supported by an award from the NCMIC Foundation.
Author details
1Department of Anesthesia, McMaster University, 1200 Main Street West,
Hamilton, Ontario L8S 4K1, Canada. 2Department of Clinical Epidemiology
and Biostatistics, McMaster University, 1200 Main Street West, Hamilton,
Ontario L8S 4K1, Canada. 3Canadian Memorial Chiropractic College, 6100
Leslie Street, Toronto, Ontario M2H 3J1, Canada. 4Faculty of Medicine,
University of Toronto, 1 Kings College Circle, Toronto, Ontario M5S 1A8,
Canada. 5Faculty of Kinesiology and Health Studies, University of Regina,
3737 Wascana Parkway, Regina, Saskatchewan S4S 0A2, Canada. 6School of
Rehabilitation Sciences, McMaster University, 1400 Main Street West,
Hamilton, Ontario L8S 1C7, Canada. 7German Hospital, Av. Pueyrredón 1640
(C1118 AAT), Buenos Aires, Argentina. 8Department of Family Medicine,
McMaster University, McMaster Innovation Park, 175 Longwood Road South,Hamilton, Ontario L8P 0A1, Canada. 9Department of Orthopaedic Surgery,
Academic Medical Center, Meibergdreef 9, 1105, Amsterdam-Zuidoost, the
Netherlands. 10Ontario Chiropractic Association, 20 Victoria Street, Suite 200,
Toronto, Ontario M5C 2N8, Canada. 11The Institute for Work & Health, 481
University Avenue, Toronto, Ontario M5G 2E9, Canada. 12Dalla Lana School of
Public Health, University of Toronto, 6th floor, 155 College Street, Toronto,
Ontario M5T 3M7, Canada. 13Stanford Prevention Research Center, Stanford
University School of Medicine, 1265 Welch Road, Stanford, CA 94305-5411,
USA. 14Knowledge and Evaluation Research Unit, Divisions of Endocrinology
and Diabetes and Health Care and Policy Research, Mayo Clinic, 200 First
Street SW, Rochester, MN 55905, USA. 15Faculty of Health Sciences, McMaster
University, 1280 Main Street West, Hamilton, Ontario L8S 4K1, Canada. 162nd
Department of Internal Medicine, Jagiellonian University Medical College, ul
Skawinska 8, 31-066, Kraków, Poland. 17Polish Institute of Evidence Based
Medicine, ul. Krakowska 41, 31-066, Kraków, Poland. 18Academy of Swiss
Insurance Medicine, University Hospital Basel, Schanzenstrasse 55, 4031, Basel,
Switzerland.
Received: 25 January 2013 Accepted: 22 February 2013
Published: 13 March 2013
References
1. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL,
Tugwell P, Campbell SM, Abeles M, Clark P, Fam AG, Farber SJ, Fiechtner JJ,
Franklin CM, Gatter RA, Hamaty D, Lessard J, Lichtbroun AS, Masi AT, McCain
GA, Reynolds WJ, Romano TJ, Russell IJ, Sheon RP: The American College
of Rheumatology 1990 Criteria for the Classification of Fibromyalgia.
Report of the Multicenter Criteria Committee. Arthritis Rheum 1990,
33:160–172.
2. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L: The prevalence and
characteristics of fibromyalgia in the general population. Arthritis Rheum
1995, 38:19–28.
3. Assumpção A, Cavalcante AB, Capela CE, Sauer JF, Chalot SD, Pereira CA,
Marques AP: Prevalence of fibromyalgia in a low socioeconomic status
population. BMC Musculoskelet Disord 2009, 10:64.
4. Branco JC, Bannwarth B, Failde I, Abello Carbonell J, Blotman F, Spaeth M,
Saraiva F, Nacci F, Thomas E, Caubère JP, Le Lay K, Taieb C, Matucci-Cerinic
M: Prevalence of fibromyalgia: a survey in five European countries.
Semin Arthritis Rheum 2010, 39:448–453.
5. Carmona L, Ballina J, Gabriel R, Laffon A, on behalf of the EPISER Study
Group: The burden of musculoskeletal diseases in the general
population of Spain: results from a national survey. Ann Rheum Dis 2001,
60:1040–1045.
6. Cöster L, Kendall S, Gerdle B, Henriksson C, Henriksson KG, Bengtsson A:
Chronic widespread musculoskeletal pain. A comparison of those who
meet criteria for fibromyalgia and those who do not. Eur J Pain 2008,
12:600–610.
7. Salaffi F, De Angelis R, Grassi W, MArche Pain Prevalence INvestigation
Group (MAPPING) study: Prevalence of musculoskeletal conditions in an
Italian population sample: results of a regional community-based study.
I. The MAPPING study. Clin Exp Rheumatol 2005, 23:819–828.
8. White KP, Speechley M, Harth M, Ostbye T: The London Fibromyalgia
Epidemiology Study: the prevalence of fibromyalgia syndrome in
London, Ontario. J Rheumatol 1999, 26:1570–1576.
9. Nöller V, Sprott H: Prospective epidemiological observations on the
course of the disease in fibromyalgia patients. J Negat Results Biomed
2003, 2:4–9.
10. Wolfe F, Anderson J, Harkness D, Bennett RM, Caro XJ, Goldenberg DL, Russell
IJ, Yunus MB: Health status and disease severity in fibromyalgia: results of a
six-center longitudinal study. Arthritis Rheum 1997, 40:1571–1579.
11. Ledingham J, Doherty S, Doherty M: Primary fibromyalgia syndrome - An
outcome study. Br J Rheumatol 1993, 32:139–142.
12. Wolfe F, Anderson J, Harkness D, Bennett RM, Caro XJ, Goldenberg DL,
Russell IJ, Yunus MB: Work and disability status of persons with
fibromyalgia. J Rheumatol 1997, 24:1171–1178.
13. Martinez JE, Ferraz MB, Sato EI, Atra E: Fibromyalgia versus rheumatoid
arthritis: a longitudinal comparison of the quality of life. J Rheumatol
1995, 22:270–274.
14. Sharpe M, Mayou R, Seagroatt V, Surawy C, Warwick H, Bulstrode C, Dawber
R, Lane D: Why do doctors find some patients difficult to help? Q J Med
1994, 87:187–193.
Busse et al. Systematic Reviews 2013, 2:18 Page 8 of 9
http://www.systematicreviewsjournal.com/content/2/1/1815. Hartz AJ, Noyes R, Bentler SE, Damiano PC, Willard JC, Momany ET:
Unexplained symptoms in primary care: perspectives of doctors and
patients. Gen Hosp Psychiatry 2000, 22:144–152.
16. Reid S, Whooley D, Crayford T, Hotopf M: Medically unexplained
symptoms - GPs' attitudes towards their cause and management.
Fam Pract 2001, 18:519–523.
17. Alegre DM, Alejandra-Pereda C, Betina-Nishishinya M, Rivera J: Systematic
review of pharmacologic treatment in fibromyalgia. Medicina Clinica 2005,
125:784–787.
18. Arnold B, Häuser W, Bernardy K, Brückle W, Friedel E, Köllner V, Kühn-Becker
H, Richter M, Weigl M, Weiss T, Offenbächer M: Multicomponent therapy
for treatment of fibromyalgia syndrome. Schmerz 2008, 22:334–338.
19. Busch AJ, Schachter CL, Peloso PM: Fibromyalgia and exercise training: a
systematic review of randomized clinical trials. Phys Ther Rev 2001,
6:287–306.
20. Busch AJ, Schachter CL, Overend TJ, Peloso PM, Barber KA: Exercise for
fibromyalgia: a systematic review. J Rheumatol 2008, 35:1130–1144.
21. Ernst E: Chiropractic treatment for fibromyalgia: a systematic review.
Clin Rheumatol 2009, 28:1175–1178.
22. Garcia-Campayo J, Magdalena J, Magallón R, Fernández-García E, Salas M,
Andrés E: A meta-analysis of the efficacy of fibromyalgia treatment
according to level of care. Arthritis Res Ther 2008, 10:R81.
23. Goldenberg DL, Burckhardt C, Crofford L: Management of fibromyalgia
syndrome. JAMA 2004, 292:2388–2395.
24. Häuser W, Bernardy K, Uçeyler N, Sommer C: Treatment of fibromyalgia
syndrome with gabapentin and pregabalin - A meta-analysis of
randomized controlled trials. Pain 2009, 145:69–81.
25. Häuser W, Bernardy K, Arnold B, Offenbächer M, Schiltenwolf M: Efficacy of
multicomponent treatment in fibromyalgia syndrome: a meta-analysis of
randomized controlled clinical trials. Arthritis Rheum 2009, 61:216–224.
26. Häuser W, Bernardy K, Uçeyler N, Sommer C: Treatment of fibromyalgia
syndrome with antidepressants: a meta-analysis. JAMA 2009, 301:198–209.
27. Jones KD, Adams D, Winters-Stone K, Burckhardt CS: A comprehensive
review of 46 exercise treatment studies in fibromyalgia (1988–2005).
Health Qual Life Outcomes 2006, 4:67.
28. Langhorst J, Häuser W, Irnich D, Speeck N, Felde E, Winkelmann A, Lucius H,
Michalsen A, Musial F: Alternative and complementary therapies in
fibromyalgia syndrome. Schmerz 2008, 22:324–333.
29. Martin-Sanchez E, Torralba E, Díaz-Domínguez E, Barriga A, Martin JL:
Efficacy of acupuncture for the treatment of fibromyalgia: systematic
review and meta-analysis of randomized trials. Open Rheumatol 2009,
3:25–29.
30. Mayhew E, Ernst E: Acupuncture for fibromyalgia–a systematic review of
randomized clinical trials. Rheumatology 2007, 46:801–804.
31. McVeigh JG, McGaughey H, Hall M, Kane P: The effectiveness of
hydrotherapy in the management of fibromyalgia syndrome: a
systematic review. Rheumatol Int 2008, 29:119–130.
32. Nishishinya B, Urrútia G, Walitt B, Rodriguez A, Bonfill X, Alegre C, Darko G:
Amitriptyline in the treatment of fibromyalgia: a systematic review of its
efficacy. Rheumatology (Oxford) 2008, 47:1741–1746.
33. Oliver K, Cronan TA, Walen HR: A review of multidisciplinary interventions
for fibromyalgia patients: where do we go from here? J Muscoskel Pain
2001, 9:63–80.
34. Schiltenwolf M, Häuser W, Felde E, Flügge C, Häfner R, Settan M,
Offenbächer M: Physiotherapy, exercise and strength training and
physical therapies in the treatment of fibromyalgia syndrome.
Schmerz 2008, 22:303–312.
35. Schneider M, Vernon H, Ko G, Lawson G, Perera J: Chiropractic
management of fibromyalgia syndrome: a systematic review of the
literature. J Manipulative Physiol Ther 2009, 32:25–40.
36. Sim J, Adams N: Systematic review of randomized controlled trials of
nonpharmacological interventions for fibromyalgia. Clin J Pain 2002,
18:324–336.
37. Sommer C, Häuser W, Berliner M, Brückle W, Ehlers S, Mönkemöller K,
Moradi B, Petzke F, Uçeyler N, Wörz R, Winter E, Nutzinger DO:
Pharmacological treatment of fibromyalgia syndrome. Schmerz 2008,
22:313–323.
38. Sultan A, Gaskell H, Derry S, Moore RA: Duloxetine for painful diabetic
neuropathy and fibromyalgia pain: systematic review of randomised
trials. BMC Neurol 2008, 8:29.39. Thieme K, Häuser W, Batra A, Bernardy K, Felde E, Gesmann M, Illhardt A,
Settan M, Wörz R, Köllner V: Psychotherapy in patients with fibromyalgia
syndrome. Schmerz 2008, 22:295–302.
40. Thomas E, Blotman F: Are antidepressants effective in fibromyalgia?
Joint Bone Spine 2002, 69:531–533.
41. Tofferi JK, Jackson JL, O'Malley PG: Treatment of fibromyalgia with
cyclobenzaprine: A meta-analysis. Arthritis Rheum 2004, 51:9–13.
42. Uceyler N, Hauser W, Sommer C: A systematic review on the effectiveness
of treatment with antidepressants in fibromyalgia syndrome. Arthritis
Rheum 2008, 59:1279–1298.
43. Arnold LM, Keck PE Jr, Welge JA: Antidepressant treatment of fibromyalgia.
A meta-analysis and review. Psychosomatics 2000, 41:104–113.
44. Hadhazy VA, Ezzo J, Creamer P, Berman BM: Mind-body therapies for the
treatment of fibromyalgia. A systematic review. J Rheumatol 2000,
27:2911–2918.
45. Karjalainen K, Malmivaara A, van Tulder M, Roine R, Jauhiainen M, Hurri H, Koes
B: Multidisciplinary rehabilitation for fibromyalgia and musculoskeletal pain
in working age adults. Cochrane Database Syst Rev 2000, 2, CD001984.
46. Merchant RE, Andre CA: A review of recent clinical trials of the nutritional
supplement Chlorella pyrenoidosa in the treatment of fibromyalgia,
hypertension, and ulcerative colitis. Altern Ther Health Med 2001, 7:79–91.
47. O'Malley PG, Jackson JL, Santoro J, Tomkins G, Balden E, Kroenke K:
Antidepressant therapy for unexplained symptoms and symptom
syndromes. J Fam Pract 1999, 48:980–990.
48. O'Malley PG, Balden E, Tomkins G, Santoro J, Kroenke K, Jackson JL:
Treatment of fibromyalgia with antidepressants: a meta-analysis.
J Gen Intern Med 2000, 15:659–666.
49. Offenbächer M, Stucki G: Physical therapy in the treatment of
fibromyalgia. Scand J Rheumatol 2000, 113:78–85.
50. Rossy LA, Buckelew SP, Dorr N, Hagglund KJ, Thayer JF, McIntosh MJ,
Hewett JE, Johnson JC: A meta-analysis of fibromyalgia treatment
interventions. Ann Behav Med 1999, 21:180–191.
51. Nüesch E, Häuser W, Bernardy K, Barth J, Jüni P: Comparative efficacy of
pharmacological and non-pharmacological interventions in fibromyalgia
syndrome: network meta-analysis. Ann Rheum Dis 2012, Jun 27
[Epub ahead of print].
52. Choy E, Marshall D, Gabriel ZL, Mitchell SA, Gylee E, Dakin HA: A systematic
review and mixed treatment comparison of the efficacy of
pharmacological treatments for fibromyalgia. Semin Arthritis Rheum 2011,
41:335–345.
53. Häuser W, Sarzi-Puttini P, Tölle TR, Wolfe F: Placebo and nocebo responses
in randomised controlled trials of drugs applying for approval for
fibromyalgia syndrome treatment: systematic review and meta-analysis.
Clin Exp Rheumatol 2012, Nov 8 [Epub ahead of print].
54. Hauser W, Bernardy K, Arnold B, Offenbächer M, Schiltenwolf M: Efficacy of
multicomponent treatment in fibromyalgia syndrome: a meta-analysis of
randomized controlled clinical trials. Arthritis Rheum 2009, 61:216–224.
55. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ,
McQuay HJ: Assessing the quality of reports of randomized clinical trials:
Is blinding necessary? Cont Clin Trials 1996, 17:1–12.
56. Berger VW: Is the Jadad Score the Proper Evaluation of Trials?
J Rheumatol 2006, 33:1710–1712.
57. Sedrakyan A, Shih C: Improving depiction of benefits and harms: analyses
of studies of well-known therapeutics and review of high-impact
medical journals. Med Care 2007, 45(Suppl 2):S23–S28.
58. Thorlund K, Walter SD, Johnston BC, Furukawa TA, Guyatt GH: Pooling
health-related quality of life outcomes in meta-analysis - a tutorial and
review of methods for enhancing interpretability. Res Synth Meth 2012,
2:188–203.
59. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, Norris S, Falck-Ytter Y,
Glasziou P, DeBeer H, Jaeschke R, Rind D, Meerpohl J, Dahm P, Schünemann
HJ: GRADE guidelines: 1. Introduction-GRADE evidence profiles and
summary of findings tables. J Clin Epidemiol 2011, 64:383–394.
60. Bucher HC, Guyatt GH, Griffith LE, Walter SD: The results of direct and
indirect treatment comparisons in meta-analysis of randomized
controlled trials. J Clin Epidemiol 1997, 50:683–691.
61. Glenny AM, Altman DG, Song F, Sakarovitch C, Deeks JJ, D’amico R,
Bradburn M, Eastwood AJ, International Stroke Trial Collaborative Group:
Indirect comparisons of competing interventions. Health Technol Assess
2005, 9:1–134. iii-iv.
Busse et al. Systematic Reviews 2013, 2:18 Page 9 of 9
http://www.systematicreviewsjournal.com/content/2/1/1862. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group: Preferred
Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA
Statement. PLoS Med 2009, 6:e1000097.
63. Turk DC, Dworkin RH, Revicki D, Harding G, Burke LB, Cella D, Cleeland CS,
Cowan P, Farrar JT, Hertz S, Max MB, Rappaport BA: Identifying important
outcome domains for chronic pain clinical trials: an IMMPACT survey of
people with pain. Pain 2008, 137:276–285.
64. Turk DC, Dworkin RH, Burke LB, Gershon R, Rothman M, Scott J, Allen RR,
Atkinson JH, Chandler J, Cleeland C, Cowan P, Dimitrova R, Dionne R, Farrar
JT, Haythornthwaite JA, Hertz S, Jadad AR, Jensen MP, Kellstein D, Kerns RD,
Manning DC, Martin S, Max MB, McDermott MP, McGrath P, Moulin DE,
Nurmikko T, Quessy S, Raja S, Rappaport BA, Rauschkolb C, Robinson JP,
Royal MA, Simon L, Stauffer JW, Stucki G, et al: Developing patient-
reported outcome measures for pain clinical trials: IMMPACT
recommendations. Pain 2006, 125:208–215.
65. Dworkin R, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP,
Kerns RD, Stucki G, Allen RR, Bellamy N, Carr DB, Chandler J, Cowan P,
Dionne R, Galer BS, Hertz S, Jadad AR, Kramer LD, Manning DC, Martin S,
McCormick CG, McDermott MP, McGrath P, Quessy S, Rappaport BA,
Robbins W, Robinson JP, Rothman M, Royal MA, Simon L, Stauffer JW, Stein
W, Tollett J, Wernicke J, Witter J: IMMPACT. Core outcome measures for
chronic pain clinical trials: IMMPACT recommendations. Pain 2005,
113:9–19.
66. Turk DC, Dworkin RH, Allen RR, Bellamy N, Brandenburg N, Carr DB,
Cleeland C, Dionne R, Farrar JT, Galer BS, Hewitt DJ, Jadad AR, Katz NP,
Kramer LD, Manning DC, McCormick CG, McDermott MP, McGrath P,
Quessy S, Rappaport BA, Robinson JP, Royal MA, Simon L, Stauffer JW, Stein
W, Tollett J, Witter J: Core outcome domains for chronic pain clinical
trials: IMMPACT recommendations. Pain 2003, 106:337–345.
67. Dworkin RH, Turk DC, Peirce-Sandner S, Baron R, Bellamy N, Burke LB,
Chappell A, Chartier K, Cleeland CS, Costello A, Cowan P, Dimitrova R,
Ellenberg S, Farrar JT, French JA, Gilron I, Hertz S, Jadad AR, Jay GW,
Kalliomäki J, Katz NP, Kerns RD, Manning DC, McDermott MP, McGrath PJ,
Narayana A, Porter L, Quessy S, Rappaport BA, Rauschkolb C, Reeve BB,
Rhodes T, Sampaio C, Simpson DM, Stauffer JW, et al: Research design
considerations for confirmatory chronic pain clinical trials: IMMPACT
recommendations. Pain 2010, 149:177–193.
68. Dworkin RH, Turk DC, McDermott MP, Peirce-Sandner S, Burke LB, Cowan P,
Farrar JT, Hertz S, Raja SN, Rappaport BA, Rauschkolb C, Sampaio C:
Interpreting the clinical importance of group differences in chronic pain
clinical trials: IMMPACT recommendations. Pain 2009, 146:238–244.
69. Turk DC, Dworkin RH, McDermott MP, Bellamy N, Burke LB, Chandler JM,
Cleeland CS, Cowan P, Dimitrova R, Farrar JT, Hertz S, Heyse JF, Iyengar S,
Jadad AR, Jay GW, Jermano JA, Katz NP, Manning DC, Martin S, Max MB,
McGrath P, McQuay HJ, Quessy S, Rappaport BA, Revicki DA, Rothman M,
Stauffer JW, Svensson O, White RE, Witter J: Analyzing multiple endpoints
in clinical trials of pain treatments: IMMPACT recommendations.
Initiative on Methods, Measurement, and Pain Assessment in Clinical
Trials. Pain 2008, 139:485–493.
70. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT,
Haythornthwaite JA, Jensen MP, Kerns RD, Ader DN, Brandenburg N, Burke
LB, Cella D, Chandler J, Cowan P, Dimitrova R, Dionne R, Hertz S, Jadad AR,
Katz NP, Kehlet H, Kramer LD, Manning DC, McCormick C, McDermott MP,
McQuay HJ, Patel S, Porter L, Quessy S, Rappaport BA, Rauschkolb C, Revicki
DA, Rothman M, Schmader KE, Stacey BR, et al: Interpreting the clinical
importance of treatment outcomes in chronic pain clinical trials:
IMMPACT recommendations. J Pain 2008, 9:105–121.
71. Akl EA, Sun X, Busse JW, Johnston BC, Briel M, Mulla S, You JJ, Bassler D,
Lamontagne F, Vera C, Alshurafa M, Katsios CM, Mills E, Guyatt GH: Specific
instructions for estimating unclearly reported blinding status in
randomized trials were reliable and valid. J Clin Epidemiol 2012,
65:262–267.
72. The Cochrane Collaboration: 16.4 Cross-over trials. In Cochrane Reviewers’
Handbook 5.1.0, Updated March 2011. 16th edition. Edited by Higgins J,
Green S. Oxford, UK: Cochrane Collaboration; 2011:14–16.21.
73. The Cochrane Collaboration: 16.1 Missing Data. In Cochrane Reviewers’
Handbook 5.1.0, Updated March 2011. 16th edition. Edited by Higgins J,
Green S. Oxford, UK: Cochrane Collaboration; 2011:2–16.7.
74. The Cochrane Collaboration: Cochrane Reviewers’ Handbook 5.1.0, Updated
March 2011. Oxford, UK: Cochrane Collaboration; 2011.75. Johnston B, Thorlund K, Schünemann HJ, Xie F, Murad MH, Montori VM,
Guyatt GH: Improving the interpretation of quality of life evidence in
meta-analyses: the application of minimal important difference units.
Health Qual Life Outcomes 2010, 8:116.
76. Thorlund K, Walter S, Johnston B, Furukawa TA, Guyatt G: Pooling health-
related quality of life outcomes in meta-analysis - a tutorial and review
of methods for enhancing interpretability. Res Synth Meth 2011,
2:188–203.
77. Higgins JPT, Thompson SG: Quantifying heterogeneity in a meta-analysis.
Stat Med 2002, 21:1539–1558.
78. Higgins JPT, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency
in meta-analyses. BMJ 2003, 327:557–560.
79. Altman DG, Bland JM: Interaction revisited: The difference between two
estimates. BMJ 2003, 326:219.
80. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH,
Harbour RT, Haugh MC, Henry D, Hill S, Jaeschke R, Leng G, Liberati A,
Magrini N, Mason J, Middleton P, Mrukowicz J, O'Connell D, Oxman AD,
Phillips B, Schunemann HJ, Edejer TT, Varonen H, Vist GE, Williams JW Jr,
Zaza S, GRADE Working Group: Grading quality of evidence and strength
of recommendations. BMJ 2004, 328:1490–1497.
81. Ades AE, Sculpher M, Sutton A, Abrams K, Cooper N, Welton N, Lu G:
Bayesian methods for evidence synthesis in cost-effectiveness analysis.
Pharmacoeconomics 2006, 24:1–19.
82. Salanti G, Higgins JP, Ades A, Ioannidis JP: Evaluation of networks of
randomized trials. Stat Methods Med Res 2008, 17:279–301.
83. Sterne JA, Davey Smith G: Sifting the evidence - what’s wrong with
significance tests? BMJ 2001, 322:226–231.
84. Lu G, Ades AE: Assessing evidence inconsistency in mixed treatment
comparisons. J Am Stat Assoc 2006, 101:447–459.
85. Mills EJ, Ioannidis JPA, Thorlund K, Schunemann HJ, Puhan MA, Guyatt GH:
How to Use an Article Reporting a Multiple Treatment Comparison
Meta-analysis. JAMA 2012, 308(12):1246–1253.
86. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P,
Schünemann HJ, for the GRADE Working Group: GRADE: an emerging
consensus on rating quality of evidence and strength of
recommendations. BMJ 2008, 336:924–926.
87. The Cochrane Collaboration: Chapter 10: Addressing reporting biases. In
Cochrane Handbook for Systematic Reviews of Interventions (Version 5.0.2).
Edited by Higgins J, Thompson SG, Oxford UK.: Cochrane Collaboration;
2010:10.1–10.33.
88. Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A,
Schünemann HJ, GRADE Working Group: Going from evidence to
recommendations. BMJ 2008, 336:1049–1051.
89. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ,
GRADE Working Group: What is "quality of evidence" and why is it
important to clinicians? BMJ 2008, 336:995–998.
90. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P,
Schünemann HJ, GRADE Working Group: GRADE: an emerging consensus
on rating quality of evidence and strength of recommendations.
BMJ 2008, 336:924–926.
doi:10.1186/2046-4053-2-18
Cite this article as: Busse et al.: Systematic review and network meta-
analysis of interventions for fibromyalgia: a protocol. Systematic Reviews
2013 2:18.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
